ABL, Inc. and Aushon BioSystems Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing
Billerica, MA and Rockville, MD, (February, 2017) Aushon BioSystems (ABS) and ABL, Inc. (ABL) today announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. Effective immediately, ABL will offer this proprietary technology as a new, exciting addition to its service offerings in support of pharmaceutical and clinical research clients.
“The adoption of the Cira platform by ABL represents another important step towards strong market adoption of our highly sensitive, multiplexing detection system for clinical applications,” said Susan Vogt, CEO of Aushon. “We’re very excited to be working with ABL and believe their adoption of the Cira platform supports our long term product strategy and commitment to growing our clinical product portfolio.”
“Implementing Aushon’s Cira platform in our GCLP clinical laboratory enables us to look deeper at biomarkers of interest, previously found to be undetectable or inconsistently quantitated by other methods. This opens exciting opportunities for ABL in evaluation of low abundance proteins, especially in a restricted volume or dilute sample. Aushon’s sensitivity and non-destructive readout is particularly useful in exploring minute changes in cytokines and other soluble biomarkers to determine possible correlates of protection, inflammatory responses, and novel signaling pathways activated in various matrices,” said Dr. Franck Lemiale, Senior Director of Immunobiology at ABL.
ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations, including industry, government and academic entities. ABL maintains U.S. and European immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. Additionally, with GMP facilities meeting U.S. and European regulatory standards, ABL’s manufacturing services include process and assay development, cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information go to: www.ablinc.com.
About Aushon BioSystems
Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the Cira™ immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laboratories worldwide. Aushon products are used for applications in preclinical and clinical biomarker research accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics. For more information go to: http://www.aushon.com.